THE ROLE OF THE GUT MICROBIOME IN THE DEVELOPMENT OF INFANTILE COLIC: A MODERN PERSPECTIVE ON ETIOPATHOGENESIS
Keywords:
infantile colic, intestinal microbiome, Limosilactobacillus reuteri, probiotics, gut–microbiota–brain axis.Abstract
Traditionally, infantile colic has been regarded as a physiological phenomenon associated with gastrointestinal immaturity and excessive gas formation. Modern pediatrics has shifted toward a neuroimmunobiological model centered on disruption of the gut–microbiome–brain axis and pathological microbial colonization during the first weeks of life. The aim of the study was to analyze the current understanding of the etiopathogenesis of infantile colic from the perspective of microbiome disturbances and to review the evidence supporting the clinical efficacy of Limosilactobacillus reuteri strains. The review included publications from PubMed, Google Scholar, and CyberLeninka, with randomized controlled trials, meta-analyses, and clinical guidelines published mainly between 2014 and 2024. Source selection focused on strict strain specificity and the reliability of diagnostic criteria (Rome IV and Wessel criteria). The “hyperergic” microbiota is characterized by reduced species diversity and predominance of Gram-negative opportunistic bacteria, especially Enterobacteriaceae such as Klebsiella and Escherichia. Their lipopolysaccharides trigger a pronounced inflammatory response, and a sharp rise in fecal calprotectin serves as a clinical marker. The resulting inflammation contributes to visceral hypersensitivity, in which normal intestinal peristalsis may be perceived as severe pain. Limosilactobacillus reuteri DSM 17938 acts through three principal mechanisms: suppression of competing microorganisms via reuterin secretion, attenuation of inflammation through regulatory T-cell activation and reduced calprotectin, and direct modulation of the enteric nervous system through inhibition of TRPV1 nociceptors. Probiotic therapy appears most effective in breastfed infants, reducing daily crying duration by 49–74 minutes with an NNT of 3. In formula-fed infants, probiotic strains have not shown statistically significant superiority over placebo.
References
1.Capozza, M., Laforgia, N., Rizzo, V., Salvatore, S., Guandalini, S., & Baldassarre, M. (2022). Probiotics and functional gastrointestinal disorders in pediatric age: A narrative review. Frontiers in Pediatrics, 10, 805466.
2.Dubois, N. E., & Gregory, K. E. (2016). Characterizing the intestinal microbiome in infantile colic: Findings based on an integrative review of the literature. Biological Research for Nursing, 18(3), 307–315.
3.Happy Tummy Consortium, Lavalle, L., Sauvageot, N., Cercamondi, C. I., Jankovic, I., Egli, D., & Vandenplas, Y. (2023). Limosilactobacillus reuteri DSM 17938-containing infant formulas and the associations with gastrointestinal tolerance: A cross-sectional observational study. Nutrients, 15(3), 530.
4.Huttenhower, C., Kostic, A. D., & Xavier, R. J. (2014). Inflammatory bowel disease as a model for translating the microbiome. Immunity, 40(6), 843–854.
5.Kamiya, T., Wang, L., Forsythe, P., Goettsche, G., Mao, Y., Wang, Y., Tougas, G., & Bienenstock, J. (2006). Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut, 55(2), 191–196.
6.Karabayır, N., Göztepe, T. O., Usta, A., Erginöz, E., & Adal, E. (2018). Fecal calprotectin as a biomarker in infantile colic. The Turkish Journal of Pediatrics, 60(4), 405–409.
7.Khavkin, A. I., Magamedova, D. M., & Novikova, V. P. (2024). Infantile colic: Facets of the problem. Pediatric Nutrition, 22(2), 60–73.
8.Khavkin, A. I., & Sitkin, S. I. (2023). The effect of targeted probiotics on the microbiota–gut–immune system axis. Clinical Practice in Pediatrics, 18(6), 107–118.
9.Lee, Y. M., Min, C. Y., Choi, Y. J., & Jeong, S. J. (2017). Delivery and feeding mode affects fecal calprotectin levels in infants <7 months old. Early Human Development, 108, 45–48.
10.Rhoads, J. M., et al. (2018). Infant colic represents gut inflammation and dysbiosis. The Journal of Pediatrics, 203, 55–61.e3.
11.Savino, F., Cordisco, L., Tarasco, V., et al. (2010). Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics, 126(3), e526–e533.
12.Skonieczna-Zydecka, K., et al. (2020). Microbiome—The missing link in the gut-brain axis: Focus on its role in gastrointestinal and mental health. Journal of Clinical Medicine, 9(12), 3817.
13.Sommermeyer, H., Bernatek, M. M., Pszczola, M., Krauss, H. H., & Piatek, J. (2022). Supporting the diagnosis of infantile colic by a point-of-care measurement of fecal calprotectin. Frontiers in Pediatrics, 10, 978545.
14.Sung, V., D'Amico, F., Cabana, M. D., Chau, K., Koren, G., Savino, F., & Tancredi, D. (2018). Lactobacillus reuteri to treat infant colic: A meta-analysis. Pediatrics, 141(1), e20171811.
15.Szajewska, H., Berni Canani, R., Domellöf, M., Guarino, A., Hojsak, I., Indrio, F., & ESPGHAN Special Interest Group on Gut Microbiota and Modifications. (2023). Probiotics for the management of pediatric gastrointestinal disorders: Position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. Journal of Pediatric Gastroenterology and Nutrition, 76(2), 232–247.
16.Zakharova, I. N., Berezhnaya, I. V., Kuchina, A. E., & Dedikova, O. V. (2019). Probiotic Lactobacillus reuteri DSM 17938: What is known about it today? Meditsinskiy Sovet = Medical Council, (17), 236–242.
17.Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., & Lebeer, S. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology, 70(4), 2782–2858.
18.Zakharova, I. N., Yatsyk, G. V., Borovik, T. E., et al. (2014). Infantile intestinal colic: A modern view of the problem. Consilium Medicum. Pediatrics, (4), 46–53.
